Three brand new studies shed light on use of natalizumab in relapsing-remitting multiple sclerosis.
Natalizumab is a highly effective therapy for relapsing-remitting multiple sclerosis. However, its efficacy in the context of other more recently available treatments needs to be assessed. Further, hampering the long-term of use of natalizumab is the association of treatment with a risk of progressive multifocal leukoencephalopathy (PML).The slides above highlight findings of 3 new studies of natalizumab.  Â
Interdisciplinary Care and Hot Topics in Movement Disorders: Jill Farmer, DO, MPH
Phase 2b Study of Parkinson Disease LRRK Inhibitor BIIB122 Initiated
AbbVie Submits sNDA for Atogepant in Chronic Migraine, Semorinemab Fails in Phase 2 Prodromal Alzheimer Study, StrivePD Software Gets FDA Greenlight
Evusheld Increased Attenuated SARS-CoV-2 Antibodies From MS B-Cell Depleting Medications